Zusammenfassung
Ewing-Sarkome sind die zweithäufigsten primären Knochentumoren im Kindes- und Jugendalter. Vordringlich ist eine rechtzeitige Diagnose. Fortbestehende lokalisierte (Knochen-)Schmerzen bei Kindern, Jugendlichen und jungen Erwachsenen müssen innerhalb von 4 Wochen differenzialdiagnostisch abgeklärt sein. Diagnostisch wegweisend ist der Nachweis der EWS-Fli1-Genfusion im Tumorgewebe. Eine intensive Kombinationschemotherapie mit mindestens 4 Medikamenten ist als Standard anzusehen. Den höchsten Stellenwert haben alkylierende Substanzen und Anthrazykline. Eine operative und/oder radiotherapeutische Lokaltherapie der Primärtumorregion ist unverzichtbar. Die Komplexität der Therapiestrategie erfordert die Therapie in spezialisierten Sarkomzentren. Mit multimodaler Therapie liegen die Heilungsraten bei lokalisierter Erkrankung >70 %. Die Prognose für Ewing-Sarkom-Patienten ist bestimmt durch die Größe des Primärtumors, den Metastasierungsstatus und das biologische Ansprechen auf initiale Chemotherapie. Die große Mehrzahl geheilter Ewing-Tumor-Patienten führt ein gesundes Leben ohne beeinträchtigende Spätfolgen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Bacci G, Mercuri M et al. (2002) Neoadjuvant chemotherapy for Ewing’s tumour of bone: recent experience at the Rizzoli Orthopaedic Institute. Eur J Cancer 38: 2243–2251
Baruchel S, Pappo A et al. (2012) A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children’s Oncology Group. Eur J Cancer 48: 579–585
Burdach S, Jurgens H (2002) High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT). Crit Rev Oncol Hematol 41: 169–189
Burgert EO Jr, Nesbit ME et al . (1990) Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: intergroup study IESS-II. J Clin Oncol 8:1514–1524
Campanacci M, Mercuri M et al. (1998) The value of imaging in the diagnosis and treatment of bone tumors. Eur J Radiol 27 Suppl 1: S116–S122
Cotterill SJ, Ahrens S et al. (2000) Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol 18: 3108–3114
Craft AW, Cotterill SJ et al. (1997) Long-term results from the first UKCCSG Ewing’s Tumour Study (ET-1). United Kingdom Children’s Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer 33: 1061–1069
De Alava E, Gerald WL (2000) Molecular biology of the Ewing’s sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 18: 204–213
Delattre O, Zucman J et al. (1994) The Ewing family of tumors – a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 331: 294–299
Dockhorn-Dworniczak B, Schäfer KL et al. (1994) Diagnostic value of the molecular genetic detection of the t(11;22) translocation in Ewing’s tumours. Virchows Arch 425: 107–112
Enneking WF (1989) Musculoskeletal tumor staging: 1988 update. Cancer Treat Res 44: 39–49
Ernst I, Scobiola S, Eich HT (2013) Rolle der Strahlentherapie bei strahlensensiblen und strahlenresistenteren Knochentumoren. Onkologe 19: 652–656
Ewing J (1921) Diffuse endothelioma of bone. Proc NY Pathol Soc 21: 17–24
Ferrari S, Palmerini E et al. (2010) Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study. Tumori 96: 213–218
Fletcher CDM et al. (eds) (2013) WHO Classification of Tumours. Tumours of soft tissue and bone. WHO Press, Geneva
Foulon S, Brennan B et al. (2016).Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group.2 Eur J Cancer 61: 128–136
Gerth HU, Juergens KU et al. (2007) Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. J Nucl Med 48: 1932–1939
Granowetter L, Womer R et al. (2003) Comparison of dose intensified and standard dose chemotherapy for the treatment of non-metastatic Ewing’s sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone and soft tissue: A Pediatric Oncology Group – Children’s Cancer Group phase III trial. Med Pediatr Oncol 37: 172
Grier HE, Krailo MD et al. (2003) Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348: 694–701
Haeusler J, Ranft A et al. (2010) The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 116: 443–450
Hayes FA, Thompson EI et al. (1989) Therapy for localized Ewing’s sarcoma of bone. J Clin Oncol 7: 208–213
Hunold A, Weddeling N et al. (2006) Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 47: 795–800
Jürgens H, Göbel V et al. (1985)The Cooperative Ewing Sarcoma Study CESS 81 of the German Pediatric Oncology Society--analysis after 4 years]. Klin Padiatr. 197: 225–232
Juergens C, Weston C et al. (2006) Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 47: 22–29
Jürgens H, Daw NC et al. (2011) Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol. 29: 4534–4540
Kovar H (1998) Ewing’s sarcoma and peripheral primitive neuroectodermal tumors after their genetic union. Curr Opin Oncol 10: 334–342
Kovar H, Alonso J et al. (2012) The first European interdisciplinary ewing sarcoma research summit. Front Oncol 2: 54
Kushner BH, Meyers PA, Gerald WL et al ( 1995) Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing’s sarcoma, in children and young adults.J Clin Oncol 13: 2796–3804
Kushner BH, Meyers PA (2001) How effective is dose-intensive/myeloablative therapy against Ewing’s sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 19: 870–880
Ladenstein R, Lasset C et al. (1995) Impact of megatherapy in children with high-risk Ewing’s tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 15: 697–705
Ladenstein R, Potschger U et al. (2010) Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial. J Clin Oncol 28: 3284–3291
Le Deley MC, Paulussen M et al. (2014) Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 Trial. J Clin Oncol 32: 2440–2448
Marina NM, Pappo AS et al. (1999) Chemotherapy dose-intensification for pediatric patients with Ewing’s family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children’s Research Hospital. J Clin Oncol 17: 180–190
Meyer WH, Kun L et al. (1992) Ifosfamide plus etoposide in newly diagnosed Ewing’s sarcoma of bone. J Clin Oncol 10: 1737–1742
Nesbit ME Jr, Gehan EA, Burgert EO et al. (1990) Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 8: 1664–1674
Oberlin O, Deley MC et al. (2001) Prognostic factors in localized Ewing’s tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 85: 1646–1654
Ozaki T, Hillmann A et al. (1996) Significance of surgical margin on the prognosis of patients with Ewing’s sarcoma. A report from the Cooperative Ewing’s Sarcoma Study. Cancer 78: 892–900
Paulussen M, Ahrens S et al. (1998) Primary metastatic (stage IV) Ewing tumor: Survival analysis of 171 patients from the EICESS studies. Ann Oncol 9: 275–281
Paulussen M, Ahrens S et al. (2001a) Localized Ewing tumor of bone: final results of the cooperative Ewing’s Sarcoma Study CESS 86. J Clin Oncol 19: 1818–1829
Paulussen M, Ahrens S et al. (2001b) Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol 12: 1619–1630
Paulussen M, Frohlich B, Jurgens H (2001c) Ewing tumour: Incidence, prognosis and treatment options. Paediatr Drugs 3: 899–913
Paulussen M, Craft AW et al. (2008) Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment – cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 26: 4385–4393
Potratz J, Dirksen U et al. (2012) Ewing sarcoma: clinical state-of-the-art. Pediatr Hematol Oncol 29: 1–11
Rodriguez-Galindo C, Spunt SL, Pappo AS (2003) Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol 40: 276–287
Rosen G, Caparros B et al. (1978) Curability of Ewing’s sarcoma and considerations for future therapeutic trials. Cancer 41: 888–899
Salzer-Kuntschik M, Delling G et al. (1983) Morphological grades of regression in osteosarcoma after polychemotherapy – study COSS 80. J Cancer Res Clin Oncol 106 (Suppl): 21–24
Schleiermacher G, Peter M et al. (2003) Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. J Clin Oncol 21: 85–91
Schuck A, Ahrens S et al. (2003) Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 55: 168–177
Smith MA, Ungerleider RS et al. (1991) Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing’s sarcoma. J Natl Cancer Inst 83: 1460–1470
Stahl M, Ranft A et al. (2011) Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 57: 549–553
Stohr W, Paulides M et al. (2007) Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: A report from the late effects surveillance system. Pediatr Blood Cancer 48: 447–452
Wagner LM, McAllister N et al. (2007) Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 48: 132–139
West DC (2000) Ewing sarcoma family of tumors. Curr Opin Oncol 12: 323–329
Winkelmann W, Jurgens H (1989) Local control in Ewing sarcoma. Comparative results following intralesional, marginal and tumor resection with healthy bone. Z Orthop Grenzgeb 127: 424–426
Womer RB, West DC et al. (2012) Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 30: 4148–4154
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Deutschland
About this chapter
Cite this chapter
Dirksen, U., Jürgens, H. (2018). Ewing-Sarkom. In: Niemeyer, C., Eggert, A. (eds) Pädiatrische Hämatologie und Onkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43686-8_28
Download citation
DOI: https://doi.org/10.1007/978-3-662-43686-8_28
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-43685-1
Online ISBN: 978-3-662-43686-8
eBook Packages: Medicine (German Language)